文献速递胸部肿瘤放疗放疗物理与技术

肺部病灶立体定向质子治疗中FLASH与分次照射在健康组织保护上的权衡

Trade-off in healthy tissue sparing of FLASH and fractionation in stereotactic proton therapy of lung lesions with transmission beams.
PubMed 文献 · Radiother Oncol · 2022-08-18

研究对12例肺癌患者的治疗计划进行分析,比较所有束流每分次照射(ABEF)与单束每分次照射(SBPF)在健康肺组织剂量和靶区适形性上的差异。SBPF导致健康肺EQD2mean中位升高54%-58%、V100% EQD2中位升高41%-236%,需FLASH增强比至少1.15-1.32才能补偿。结论认为SBPF中FLASH效应可能超过分次照射的损失,但取决于FLASH效应发生的条件。

要点

  • SBPF较ABEF使健康肺EQD2mean中位升高54%-58%,V100% EQD2中位升高41%-236%。
  • 补偿损失所需FLASH增强比:EQD2mean至少1.23-1.32,V100% EQD2至少1.15-1.29。
  • SBPF中FLASH效应可能超过分次照射损失,但取决于FLASH效应发生条件。

核心结论

  • 在立体定向肺部治疗中,SBPF的FLASH效应可能超过分次照射的损失,但权衡取决于FLASH效应发生的条件。
  • 需要更好地理解潜在生物学和照射条件的影响。

研究设计与样本

  • 研究为治疗计划研究,纳入12例肺癌患者,GTV勾画可用,应用5 mm GTV-PTV外扩。
  • 使用3、5、7、9个244 MeV质子透射束的等角布置,分次数等于束流数以实现SBPF。
  • 采用单野均匀剂量处方的等有效分次方案:D95%,PTV = 100%Dpres每束。
  • 评估FLASH增强生物等效剂量(EQD2)的肺剂量和靶区适形性。

主要发现

  • 与ABEF相比,SBPF在3、5、7、9分次计划中健康肺EQD2mean中位分别升高56%、58%、55%和54%。
  • 与ABEF相比,SBPF在3、5、7、9分次计划中V100% EQD2中位分别升高236%、78%、50%和41%。
  • 补偿EQD2mean升高所需FLASH增强比至少分别为1.28、1.32、1.30和1.23。
  • 补偿V100%,EQD2升高所需FLASH增强比至少分别为1.29、1.18、1.28和1.15。

关键数值与推荐

  • FLASH效应可能需剂量率阈值40-100 Gy/s和剂量>3.5-7 Gy。
  • SBPF中分次数等于束流数,采用单野均匀剂量处方D95%,PTV = 100%Dpres每束。
  • 健康肺EQD2mean升高的补偿FLASH增强比:3分次1.28、5分次1.32、7分次1.30、9分次1.23。
  • V100%,EQD2升高的补偿FLASH增强比:3分次1.29、5分次1.18、7分次1.28、9分次1.15。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要更好地理解潜在生物学和照射条件的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE AND OBJECTIVE: Besides a dose-rate threshold of 40-100 Gy/s, the FLASH effect may require a dose > 3.5-7 Gy. Even in hypofractioned treatments, with all beams delivered in each fraction (ABEF), most healthy tissue is irradiated to a lower fraction dose. This can be circumvented by single-beam-per-fraction (SBPF) delivery, with a loss of healthy tissue sparing by fractionation. We investigated the trade-off between FLASH and loss of fractionation in SBPF stereotactic proton therapy of lung cancer and determined break-even FLASH-enhancement ratios (FERs). MATERIALS AND METHODS: Treatment plans for 12 patients were generated. GTV delineations were available and a 5 mm GTV-PTV margin was applied. Equiangular arrangements of 3, 5, 7, and 9 244 MeV proton transmission beams were used. To facilitate SBPF, the number of fractions was equal to the number of beams. Iso-effective fractionation schedules with a single field uniform dose prescription were used: D95%,PTV = 100%Dpres per beam. All plans were evaluated in terms of dose to lung and conformity of dose to target of FLASH-enhanced biologically equivalent dose (EQD2). RESULTS: Compared to ABEF, SBPF resulted in a median increase of EQD2mean to healthy lung of 56%, 58%, 55% and 54% in plans with 3, 5, 7 and 9 fractions respectively and of 236%, 78%, 50% and 41% in V100% EQD2, quantifying conformity. This can be compensated for by FERs of at least 1.28, 1.32, 1.30 and 1.23 respectively for EQD2mean and 1.29, 1.18, 1.28 and 1.15 for V100%,EQD2. CONCLUSION: A FLASH effect outweighing the loss of fractionation in SBPF may be achieved in stereotactic lung treatments. The trade-off with fractionation depends on the conditions under which the FLASH effect occurs. Better understanding of the underlying biology and the impact of delivery conditions is needed.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Habraken S, Breedveld S, Groen J, et al. Trade-off in healthy tissue sparing of FLASH and fractionation in stereotactic proton therapy of lung lesions with transmission beams. Radiother Oncol. 2022. PMID: 35988773. doi:10.1016/j.radonc.2022.08.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。